Member Info for inanaco

Icalvert Plan to auction .. ? what ebay .

The £50m value relates to what the remuneration committee of scancell placed on the value of a single immunobody vaccine. So just using that as a ref. point gives you some indication of how the BOD consider the values of upfront payment deals.

Tf you owe me the next lunch 100%

and i also agreed with Wild that my opinion is just my opinion and those present a challenge are trying to express there opinion as the dominant ... however risk is personal so it makes no difference at all except for one point

i actually put the meat on the bone as to why i consider the risk at this SP at zero because i consider the principle asset SCIB1 as the product that can carry the value regardless in any deals done today or after the combo trial.

you have not understood what i posted ...

its all down to how you value the current immunobody validated platform today ... and how that value is reflected in the current share price.

the reason why you get yourself so tangled up is when i posted to you yesterday you did not answer

SCLPHotw1ngsWed 16:35
question for you

what is the first line treatment for melanoma after surgery

at least i have my own Spell checker and grammar correction service in attendance ... who else has a living spell checker ? will add a few more errors keep him in toe ...

exactly C7 ... so why do so many make such of fuss over my opinion , to try to present there opinion

what i can say time will prove who is correct ....

lol ... so basically the message we should all put out is " Scancell is an extremely risky share but at this price its not risky to hold" LOL

you best sell than ..

you have not nailed down anything ..

C7 i do not have to justify anything

Risk is how its perceived by others ...

my posts clearly mitigate it with very fine factual detail on the science, including constant cross ref to other research papers which identifies overlap, which is like having Lindy's work Peer reviewed, its not me doing that review but other scientists, all i am doing is saying Hey Look ! and drawing a conclusion.

Now unless you can keep up and follow those research papers, you would be completely baffled by what i post.

But that does not mean my posts are incorrect or indeed remove's perceived risk from those that cannot follow it

hence this constant battle with those that are not fully engaged with the science or like Boom did today actually create Fake News

it has not been created because scancell has proceed with the lead vaccine SCIB1 ..which is validate the immunobody platform

the risk to shareholders would have been created if it had "not" invested as clearly scancell would have felt the product was not worth pursuing thus you can then apply high risk to the platform

are you simple ?

the post clearly states "if the BOD did not think a deal was possible"

what is your problem Hotw1ngs .. i tell you who you remind me of Owen Jones ...

what i would say, If the BOD did not think a deal was possible, why are they continuing to invest in SCIB1 when they have such a diverse pipeline to expand further, by passing all the risk of the immunobody program onto CRUK to prove it, at no cost to scancell shareholders ?

filibuster posting is of no interest Hotw1ngs .. unless you have something of interest i am afraid you will be ignored, it is not the case that i won't discuss scancell with those that have no idea how it functions, its just that your input is disruptive and worthless in context

you cannot read, the risk factor would only be applied if Scancell did not proceed to invest in SCIB1 thus passing the immunbody lead program to scib2 funded by CRUK

as this is not the case then the Risk factor is removed. as Scancell is committed to the SCIB1 program

how simple do i have to make the posts ?

Hotw1ngs

Scancell’s Immunobody® immunotherapy platform enhances the uptake and presentation of cancer antigens to harness the high avidity T cell responses that destroy tumours. The platform has been validated both in animals and in the clinic with SCIB1 but many opportunities also exist for the development of additional ImmunoBody® vaccines, both for cancer and chronic infectious diseases.

notice scancell use the words """""" has been validated """"""""""

this is why you cannot apply risk to its current status as a validated platform because its already proven to its current position.

thing is we are not waiting for the 10% feel good factor, what we are waiting for is the first real deal that expresses true value of the work that scancells doing, which has already been recognised by
BioNtech
ISA pharma
Genentech
Karolinska Institutet
Cancer Research UK

and a host of the Best Brains in oncology

and yet on here attempts to portray scancell as Risky by individuals with no serious medical background feel they know more than the above ....

Hotw1ngs we have not passed on immunobody to CRUK to prove, Scancell is doing it with SCIB1, please keep up

The question you always have to ask .. is

why does the other party in any negotiation want for its shareholders ?

and what does the Scancell board want for its shareholders ? (considering the BOD hold a serious position)

notice both have something in common ... Shareholders both want Value

Now we know vaccines fell out of favour because of the high failure rate by some big player, who diverted very quickly into control of the environment ie PD1 and the CTL4 check points

because they have become the "standard of Care" the combinations that can perform with them are the next wave which now brings back in the Vaccines again, so the market has again turned positive for Scancell

just need the Data ...

what i would say, If the BOD did not think a deal was possible, why are they continuing to invest in SCIB1 when they have such a diverse pipeline to expand further, by passing all the risk of the immunobody program onto CRUK to prove it, at no cost to scancell shareholders ?

SCLPRE: Thanks Ivey and TFWed 21:20
Ivy i will not have this debate unless you have factual evidence that can show how it can fail.

you never responded ...

Its not as if i don't have experience on predicting scancells trials ...

from the Phase 1 data i predicted the phase two data would be a "walk in the park" well that turned out to be exceptional ...

i had all the furore then to for even suggesting it.

Give over ....

Boom is very precise, but failed on the biggest measure here of understanding how interferon gamma induces the moditope epitope to display, it took me days to convince, and indeed he only throw in the towel when wild used the word "catalyst"

Boom had to intervene to cover your back once i set YOU that very challenging question yesterday, which you did not respond to. Now you are attempting to cover his back

blindly obvious that you are trying to elevate each other for some obscure reason that you think these BB's have influence. well they don't, the influence is only conveyed to existing holders, rarely influence new buyers because with the best will in the world it would take me Hours to compile posts explaining scancell, even the hardman report is becoming a manual ...

which is why i tried the step by step approach of weighting the science to risk ... but even that becomes a fight

Exactly wild,

I keep trying to point out that we are not dealing with Brand new never tried drugs before ...

we are dealing with a proven vaccine in 30 plus patients

and a proven check point inhibitor treating 1000.s

Scancell has collected so much evidence that nobody seems to be able to refute ... and the point being if scancell felt it could not achieve value in only 25 patients why do it ?